Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835159 · ClinicalTrials.gov registry record · Phase 4
Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00835159: Completed Phase 4 study, sponsored by NYU Langone Health.
NCT00835159 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00835159, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether preoperative administration of Rivastigmine prevents the incidence of postoperative delirium in patients undergoing major surgery as well as postoperative cognitive dysfunction.
Primary Outcome
Is the incidence of POD not affected by rivastigmine treatment or not.
Interventions
- OTHER Placebo Patch
- DRUG Rivastigmine Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-10 |
| Phase | Phase 4 |
What the finished NCT00835159 record still lists
NCT00835159 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Patch is the first listed.
NCT00835159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00835159 about?
NCT00835159 is a clinical study titled "Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial". The purpose of this study is to determine whether preoperative administration of Rivastigmine prevents the incidence of postoperative delirium in patients undergoing major surgery as well as postoperative cognitive dysfunction.
What is the current status of trial NCT00835159?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2008-12. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00835159?
The interventions under investigation include: Placebo Patch (OTHER), Rivastigmine Patch (DRUG).
Who is sponsoring clinical trial NCT00835159?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00835159's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia